ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
49 announcements with these filters
Natco Pharma promoter V.C. Nannapaneni pledged 8,50,000 equity shares to Bajaj Financial Securities Limited. The pledge supports the promoter's subscription to the company's Rights Issue.
Natco Pharma filed its shareholding pattern with a reporting date of 23 October 2026. Promoter and promoter group hold about 46% of total equity.
Natco Pharma allotted 5,86,666 equity shares to promoter Venkaiah Chowdary Nannapaneni via its rights issue, valued at ~₹44 Crore. This lifts his stake to 14.60%.
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
Natco Pharma will hold a board meeting on 13 November 2026 to consider unaudited quarterly results and an interim dividend. Trading window closed until 15 November 2026.
Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.
Natco Pharma launches Carboplatin Injection, a Paraplatin® generic, in the U.S. market via its subsidiary. The oncology product addresses a critical U.S. supply shortage.
Natco Pharma Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance submission.
Promoter V.C. Nannapaneni pledged 850,000 shares of Natco Pharma, valued at ₹67.10 Crore. This pledge creation increases encumbrance on promoter shareholding.
Natco Pharma shareholders approved fund raising of up to Rs. 2,000 Crore through various instruments, along with other routine AGM resolutions.
Natco Pharma held its 43rd Annual General Meeting on September 30, 2026. Shareholders approved all agenda items, including a fund-raising authorisation limit of Rs. 2,000 Crore.
Natco Pharma Limited conducted its 43rd Annual General Meeting on September 30, 2026. Shareholders considered a proposal to raise up to ₹2,000 Crore through various equity instruments.
Natco Pharma Limited increased its investment in US-based biotechnology firm eGenesis, Inc. to $16.70 million. This follows a previous commitment of $14.00 million through its global subsidiaries.
Natco Pharma's board has approved a Rights Issue to raise ₹1,279.36 Crore. The company will issue 17,058,082 equity shares at ₹750 each in a 2:21 ratio.
Natco Pharma's board approved a Rights Issue of 1,70,58,082 shares aggregating to ₹1,279.36 Crore. The issue is priced at ₹750 per share with a 2:21 ratio.
Natco Pharma will hold a board meeting on 25th September 2026 to finalise terms for its previously approved rights issue, including pricing and record date.
Natco Pharma has received in-principle approval from BSE and NSE for its upcoming Rights Issue of fully paid-up equity shares.
Natco Pharma proposes a Rights Issue of equity shares aggregating up to ₹1,300 Crore. The company has filed the Draft Letter of Offer for this capital raise.
Natco Pharma board approved a rights issue of up to ₹1,300 crore face value ₹2 equity shares. The demerger scheme will be revised post-completion of the raise.
Natco Pharma Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26.
Natco Pharma issued the notice for its 43rd Annual General Meeting to be held on September 30, 2026, covering agenda items including director appointment and fund-raising.
Natco Pharma filed its Annual Report for FY 2025-26 as required under SEBI regulations. The 43rd AGM is scheduled for September 30, 2026.
Natco Pharma Limited has scheduled a board meeting for September 9, 2026, to discuss potential fund-raising proposals.
Natco Pharma promoter Durga Devi Nannapaneni gifted 50,000 equity shares to her niece. The off-market transfer reduces her stake from 1.98% to 1.95%.
Natco Pharma Limited's subsidiaries will invest Rs 134.01 Crore in eGenesis, Inc., a US-based biotechnology company. The investment involves subscribing to 8% convertible promissory notes.
NATCO Pharma Limited is investing US$ 14 million (approx. ₹133 Crore) in eGenesis, Inc. via convertible promissory notes. This increases NATCO's total investment in the biotechnology firm to US$ 22 million.
Natco Pharma concluded a US FDA inspection at its Visakhapatnam FDF unit. The inspection resulted in 4 procedural observations, which the company intends to address.
NATCO reported Q1 FY27 consolidated revenue of INR 794.4 Cr and PAT of INR 206.5 Cr. Performance was driven by base business growth and a strong flu season at associate Adcock Ingram.
Natco reported a sharp revenue decline due to lower Revlimid contributions, masked by strong growth in Brazil and domestic segments.
Natco Pharma reported Q1 FY27 revenue of INR 7,944 Mn and Net Profit of INR 2,065 Mn. Strategy focuses on high-barrier US formulations and NCE/Cell & Gene therapy investments.